Jyoti D. Patel, MD

Jyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.

Jyoti D. Patel, MD, discusses immunotherapy combinations for patients with advanced nonsquamous non–small cell lung cancer.

Jyoti D. Patel, MD, discusses current immunotherapy options in stage IV non–small cell lung cancer.

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.

Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.